News | Point of Care Testing | October 13, 2015

Study Shows Abbott’s High-Sensitive Troponin Test May Rule Out Myocardial Infarction Faster

Faster testing could lead to earlier discharge of majority of emergency patients with chest pain

The Lancet results, Abbott ARCHITECT STAT High Sensitive Troponin-I test, rule out myocardial infarction, Accident and Emergency, A&E

October 13, 2015 — The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may rule out myocardial infarction (MI) in two-thirds of very-low risk patients, allowing prompt discharge from A&E (Accident and Emergency). The study identified a precise new threshold of troponin of <5 ng/L which, together with other clinical factors, allows doctors to rule out heart attacks in the majority of patients, reducing prolonged waiting for monitoring with additional tests, unnecessary procedures and hospital admissions.

The study was funded by a special project grant from the British Heart Foundation and conducted by researchers at the University of Edinburgh.

Abbott’s high-sensitive test precisely measures very low levels of cardiac troponin, a protein which at increased levels can indicate injury to the heart. The use of the test helped researchers establish the optimal threshold, which resulted in an overall negative predictive value (the probability that a negative test result is a true negative) of 99.6 percent. The percentage was similar for men and women, across age groups and in patients with prior cardiovascular disease.

“The results show the high sensitive test can help doctors determine with an extremely high level of confidence that a patient may be at low risk of myocardial infarction and therefore can be safely discharged from A&E,” said Atul Anand, M.D., one of the study authors from the University of Edinburgh and Edinburgh Royal Infirmary. “This newly identified threshold has the potential to change how we diagnose patients presenting with chest pain. By establishing a troponin threshold that allows the greatest proportion of patients to be safely discharged, we have the potential to improve patient care and prevent unnecessary hospital admissions and procedures.”

In England and Wales, chest pain accounts for approximately 700,000 visits to A&E each year and patients with suspected acute coronary syndrome (ACS) are commonly admitted to hospital in order to rule out MI. Currently doctors who administer high sensitive troponin blood tests at admission, do so again within 12 hours to evaluate whether or not patients are having heart attacks. This study suggests that by using the newly identified troponin testing level, doctors have the potential to double the number of patients who are discharged directly from A&E following a single, baseline troponin test. In addition, this may provide an opportunity to lower costs incurred by healthcare systems overall.

For more information: www.abbottdiagnostics.com

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init